Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alessandro Follador
Observed names:
A. Follador,
FOLLADOR, Alessandro,
Follador, Alessandro
Institution:
Azienda sanitaria universitaria Friuli Centrale
Observed institutions:
University of Udine,
University of Leeds,
Italian Oncology Group of Clinical Research,
Azienda Ospedaliera Santa Maria Degli Angeli,
Ospedale Santa Maria della Misericordia di Udine,
Azienda sanitaria universitaria Friuli Centrale
show all 6
ORCID:
0000-0002-2168-4574
Observed ORCID:
0000-0002-2168-4574
OpenAlex ID:
A5004048756
Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications
2005
·
F. Puglisi
, A. Follador
, et al.
·
Annals of Oncology
·
171
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
2011
·
P.A. Zucali
, M. Simonelli
, et al.
·
Lung Cancer
·
111
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020
·
Alessio Cortellini
, Alex Friedlaender
, et al.
·
Clinical Lung Cancer
·
93
PDF
Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial—An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002)
2007
·
Gianpiero Fasola
, Ornella Belvedere
, et al.
·
The Oncologist
·
92
PDF
Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study
2008
·
Gianpiero Fasola
, Marianna Aita
, et al.
·
BMC Health Services Research
·
85
PDF
Drug waste minimization as an effective strategy of cost-containment in Oncology
2014
·
Gianpiero Fasola
, Giuseppe Aprile
, et al.
·
BMC Health Services Research
·
84
PDF
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
2021
·
Martina Lorenzi
, Alessandra Ferro
, et al.
·
The Oncologist
·
79
PDF
Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature
2007
·
Francesco Grossi
, Marianna Aita
, et al.
·
The Oncologist
·
72
Unplanned presentations of cancer outpatients: a retrospective cohort study
2012
·
G. Aprile
, F. E. Pisa
, et al.
·
Supportive Care in Cancer
·
57
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
2021
·
Alessio Cortellini
, Andrea De Giglio
, et al.
·
Thoracic Cancer
·
52
PDF
Immunotherapy in NSCLC Patients with Brain Metastases
2022
·
Silvia Buriolla
, Giacomo Pelizzari
, et al.
·
International Journal of Molecular Sciences
·
51
PDF
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
2024
·
David R. Spigel
, Afshin Dowlati
, et al.
·
Journal of Clinical Oncology
·
50
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
2017
·
Sara Pilotto
, Antonio Rossi
, et al.
·
Clinical Lung Cancer
·
49
The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice
2021
·
Giovanna De Maglio
, Giulia Pasello
, et al.
·
Critical Reviews in Oncology/Hematology
·
46
PDF
MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma Multiforme
2018
·
Lorena Gurrieri
, Elisa De Carlo
, et al.
·
Future Oncology
·
42
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
2021
·
Sebastiano Buti
, Melissa Bersanelli
, et al.
·
European Journal of Cancer
·
37
Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer
2008
·
Marianna Aita
, Gianpiero Fasola
, et al.
·
Critical Reviews in Oncology/Hematology
·
33
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
2019
·
A. Cortellini
, A. Leonetti
, et al.
·
Clinical & Translational Oncology
·
29
PDF
Emerging therapies in malignant pleural mesothelioma
2019
·
Marika Cinausero
, Karim Rihawi
, et al.
·
Critical Reviews in Oncology/Hematology
·
27
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014)
2010
·
Francesco Grossi
, Riccardo Spizzo
, et al.
·
Journal of Thoracic Oncology
·
26
PDF
Health Information Technology in Oncology Practice: A Literature Review
2014
·
G. Fasola
, M. Macerelli
, et al.
·
Cancer Informatics
·
24
PDF
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers
2018
·
Fabio Barbone
, Fabiano Barbiero
, et al.
·
International Journal of Epidemiology
·
23
PDF
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
2021
·
S. Novello
, V. Torri
, et al.
·
Annals of Oncology
·
22
PDF
Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report
2006
·
Gianpiero Fasola
, Fabio Puglisi
, et al.
·
BMC Cancer
·
18
PDF
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024
·
Alessandro Leonetti
, Fabiana Perrone
, et al.
·
European Journal of Cancer
·
17
PDF
Show more works
View as search
Works count:
114
Citation count:
1,621
H-index:
22
I10-index:
35
Year
Topic
Type